Sign up USA
Proactive Investors - Run By Investors For Investors

Amgen up after judge rules rivals must pull a competing cholesterol drug off the market

District Judge Sue Robinson in Delaware announced a ban on Regeneron and Sanofi from selling their cholesterol drug, Praluent on the grounds of patent infringement.
Drugs
However, Judge Robinson ordered that the ban not take effect for 30 days to give Sanofi and Regeneron time to appeal

Shares in Amgen Inc. (NASDAQ:AMGN) rose today after a US Federal judge ruled that two of the pharma firm's rivals must pull a competing cholesterol drug off the market.

Late yesterday, District Judge Sue Robinson in Delaware announced a ban on Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and French firm Sanofi SA from selling their cholesterol drug, Praluent in the US on the grounds of patent infringement.

Amgen had sought a ban in an October 2014 lawsuit against the two firms claiming that Praluent, which lowers so-called "bad" cholesterol by blocking a protein known as PCSK9, infringed its patents related to that protein.

Blocking sales of Praluent, the judge said that "irreparable harm" had been done to Amgen's own cholesterol-lowering treatment, Repatha.

In early New York trading today, Amgen shares jumped 3% higher to $157, while shares in Regeneron dropped over 6% to $356.

However, Judge Robinson ordered that the ban not take effect for 30 days to give Sanofi and Regeneron time to appeal, which they said they would do.

In a statement today, Sanofi's executive vice president Karen Linehan said: “"It is our longstanding position that Amgen's patent claims are invalid and that the best interests of patients will be greatly disserved by an injunction preventing access to Praluent."

A jury found Amgen's patents were valid in March.

Commentators said the companies could still decide to reach a settlement that would give Amgen royalties on Praluent sales.

The US Food and Drug Administration approved Praluent and Repatha in 2015, and both are currently in final stage trials.



Register here to be notified of future AMGN Company articles
View full AMGN profile

Amgen Timeline

Newswire
August 26 2013

Related Articles

picture of pregnant woman
October 10 2016
Stem cell therapies are tipped to be among the next great advances in the treatment of a range of life-threatening ailments and conditions.
Harley Street London street sign
May 27 2016
The cancer treatment specialist has received funding to bring its breakthrough therapy to London.
Genetic data
July 12 2016
Drug discovery company snaps up software system for "non-material" sum
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use